# NRDL

China’s Million-Yuan Cancer Gamble: High-Stakes Negotiations Begin for CAR-T Therapies

China's healthcare authorities have included two high-priced CAR-T therapies in the preliminary 2026 reimbursement review, utilizing a new commercial insurance pathway. This move signals a strategic shift toward a multi-tiered payment system to accommodate expensive medical innovations while managing state budget constraints.